|
Nov 29
|
Adaptimmune Receives Transfer of IND for Lete-cel Program
|
|
Nov 13
|
Adaptimmune Therapeutics PLC (ADAP) Loses -28.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
|
|
Nov 13
|
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q3 2023 Earnings Call Transcript
|
|
Nov 9
|
Forecast: Analysts Think Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Business Prospects Have Improved Drastically
|
|
Nov 8
|
Adaptimmune Reports Third Quarter Financial Results and Business Update
|
|
Nov 8
|
Adaptimmune Selects ADP-600 as Clinical Candidate for Best-in Class PRAME Strategy
|
|
Nov 7
|
Adaptimmune Therapeutics PLC (ADAP) Surpasses Market Returns: Some Facts Worth Knowing
|
|
Oct 31
|
Adaptimmune Reports Better Outcomes for People with Synovial Sarcoma who Received Afami-cel Compared to Historical Control
|
|
Oct 31
|
Adaptimmune Reports Positive Data with Lete-cel[1] from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS
|
|
Aug 9
|
Adaptimmune Reports Second Quarter Financial Results and Business Update
|